DAVID COFFMAN: Open Payments
NPI 1578851739 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,855 in 146 payments from 19 companies in 2025. Trend: 2023 $3,009 · 2024 $2,668 · 2025 $2,855
Food & beverage: $2,855
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $424 |
| Otsuka America Pharmaceutical, Inc. | 15 | $338 |
| Neurocrine BioSciences, Inc. | 10 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $244 |
| Axsome Therapeutics, Inc. | 7 | $228 |
| Corium, LLC | 10 | $228 |
| ABBVIE INC. | 22 | $210 |
| Lundbeck LLC | 12 | $204 |
| Supernus Pharmaceuticals, Inc. | 11 | $188 |
| Janssen Pharmaceuticals, Inc | 6 | $111 |
Products named: REXULTI, CAPLYTA, INGREZZA, TRINTELLIX, Auvelity, Azstarys, VRAYLAR, Qelbree.
Industry payments across AL — which companies pay providers there.
